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Abstract Urothelium, one of the slowest cycling epithelia in
the body, embodies a unique biological context for cellular
transformation. Introduction of oncogenes into or removing
tumor suppressor genes from the urothelial cells or a
combination of both using the transgenic and/or knockout
mouse approaches has provided useful insights into the
molecular mechanisms of urothelial transformation and
tumorigenesis. It is becoming increasingly clear that over-
activation of the receptor tyrosine kinase (RTK) pathway, as
exemplified by the constitutively activated Ha-ras oncogene,
is both necessary and sufficient to initiate the low-grade,
non-invasive urothelial carcinomas. Dosage of the mutated
Ha-ras, but not concurrent inactivation of pro-senescence
molecules p16Ink4a and p19Arf, dictates whether and when
the low-grade urothelial carcinomas arise. Inactivation of
both p53 and pRb, a prevailing paradigm previously
proposed for muscle-invasive urothelial tumorigenesis, is
found to be necessary but insufficient to initiate this
urothelial carcinoma variant. Instead, downregulation in
p53/pRb co-deficient urothelial cells of p107, a pRb family
member, is associated with the genesis of the muscle-
invasive bladder cancers. p53 deficiency also seems to be
capable of cooperating with that of PTEN in eliciting
invasive urothelial carcinomas. The genetically engineered
mice have improved the molecular definition of the divergent
pathways of urothelial tumorigenesis and progression, helped
delineate the intricate crosstalk among different genetic
alterations within a urothelium-specific context, identified
new prognostic markers and novel therapeutic targets
potentially applicable for clinical intervention, and provided
in vivo platforms for testing preventive strategies of bladder
cancer.
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1 Introduction
Tumors are a phenotypic manifestation of genomic, genetic,
and epigenetic abnormalities [1–3]. While few tissues can
escape tumorigenesis, the vulnerability of different tissues to
a given oncogenic alteration or several well-defined onco-
genic alterations varies considerably. Evidence is mounting
that this divergent vulnerability, generally referred to as
tissue-specificity or cellular context-dependency of tumori-
genesis, is more of a rule than an exception [4]. At the heart
of this concept is the critical contribution of intrinsic
biological properties of an affected tissue to oncogenic
processes. Compelling evidence exists, from both human
patients and animal models, supporting the cell-type-
dependent tumorigenicity by a range of oncogenic alter-
ations. For instance, germline mutations of adenomatosis
polyposis coli (APC) gene in humans affect primarily the
colorectal epithelial cells, predisposing them to adenoma
formation [5–7]. Patients with germline mutations in von
Hippel-Lindau (VHL) gene are particularly prone to devel-
oping early-onset renal cell carcinomas [8, 9]. Germline
mutations of p53 gene, which cause Li-Fraumeni syndrome,
preferentially transform soft tissues and mammary gland into
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malignancies [10, 11]. Patients with Costello syndrome,
which is caused by germline mutations in the Ha-ras
oncogene, are highly susceptible to tumor development in
skeletal muscle and bladder urothelial cells [12, 13]. This
type of tissue-selectivity in tumor susceptibility has been
reproduced in genetically engineered animals as well. Thus,
global inactivation of p53 gene in mice leads to a high
incidence of thymic lymphomas and soft tissue sarcomas
while sparing most other tissues from early-onset tumori-
genesis [14]. Transgenic expression of the same oncogene or
conditional abrogation of the same tumor suppressor gene in
different tissues under the control of tissue-specific pro-
moters also frequently results in significant variations in
tumor initiating ability, phenotype, latency, and penetrance
[15–18]. These and many other examples are strongly
indicative of the fundamental role that the cellular context
plays in influencing whether and when tumorigenesis takes
places under a well-defined genetic circumstance.
Precisely why different tissues respond to oncogenic
assaults drastically differently remains poorly understood.
While still evolving, the phenomenon may be a result of an
intricate interplay of multiple intrinsic factors within a
given tissue. These may include, but not necessarily be
limited to, the steady-state proliferation rate of a tissue, the
mode of baseline signal wiring, the microenvironment, the
accessibility to growth factors and the level of growth
factor receptor expression, the ability (or the lack thereof)
to mount an effective tumor defense against genotoxins via
senescence, apoptosis, and DNA damage response, the
balance and collaborative arrangements between growth
promoters and inhibitors, and so on. In this review, I will
focus on the biological aspects of urothelial tumorigenesis
based primarily on recent data obtained from transgenic and
knockout mouse models, with reference to human bladder
cancer whenever appropriate. Information learned from
xenograft and orthotopic bladder cancers and chemical
carcinogenesis models will not be discussed here and readers
are referred to several reviews published previously [19–21].
2 Unique context of urothelium in tumorigenesis
Urothelium, from which all the urothelial tumors originate,
is a highly specialized epithelium [22–24]. Situated
strategically between the urine and blood, normal urothe-
lium acts as a physiologically effective and mechanically
flexible permeability barrier that on the one hand protects
the underlying tissues from toxic urinary substances and on
the other hand adjusts its surface area actively and
reversibly during the micturition cycle [25, 26]. To satisfy
the requirement for stability, urothelium cycles extremely
slowly, with a turnover rate of about 200 days and a tritium-
thymidine labeling index of less than 0.01% [27, 28].
Histologically a stratified and polarized epithelium, urothe-
lium is comprised of a single-cell type with phenotypic
differences between different cell layers attributed to the
different degree of cellular differentiation. Cells in the basal
layer are the smallest in size and least differentiated, and
this is where the proliferative compartment and stem cells
are believed to reside [29]. While the basal layer is the only
urothelial layer that expresses an appreciable level of
epidermal growth factor (EGF) receptor [30, 31], this layer
is inaccessible to the exceedingly high concentration of
EGF in the urine, due to the barrier provided by the
superficial urothelial layer [32]. Similarly, urothelial basal
cells are normally well protected from an assortment of
urinary carcinogens. The basal cells can differentiate to
become intermediate cells whose layer thickness depends
on the species (one layer in rodents and 3–4 layers in
humans) [22]. Although the basal and intermediate urothe-
lial cells are hardly distinguishable morphologically from
their counterparts in other stratified epithelia, the superficial
urothelial cells facing the bladder lumen, nick-named
“umbrella cells”, are highly distinct. These are large
(~100 μm in diameter in rodents), polyhedral, and often
bi-nucleated cells, thought to be derived from the interme-
diate cells via cell–cell fusion [33, 34]. Unlike any other
cells in the body, the umbrella cells elaborate a membrane
specialization, called asymmetric unit membrane (AUM),
that lines over 95% of the apical surface of the urothelium
as well as all the cytoplasmic fusiform vesicles [33–35]. It
has been established that AUM is comprised of four major
uroplakins (Ia, Ib, II and IIIa), and one minor uroplakin
(IIIb), all of which are highly restricted to the urothelium
[36–43]. While functionally active in synthesizing and
assembling large amounts of uroplakins, the umbrella cells
are considered to be terminally differentiated and incapable
of undergoing cell division [22, 44], although some
questions remain as to whether the umbrella cells can re-
enter the cell division cycle [45].
3 Urothelial response to pRb deficiency
It was unclear until recently as to why in molecular terms
normal urothelium maintains an extremely low cycling rate.
In addition to the lack of exposure of its basal cells to the
urinary growth stimuli, urothelial cells are under the tight
control of negative cell-cycle regulators. While p53,
p16Ink4a, and p19Arf are consistently undetectable immu-
nohistochemically [46, 47], all pRb family proteins,
including pRb itself, p107 and p130, are uniformly
expressed by all urothelial layers [48]. It appears, therefore,
that the pRb family proteins play a redundant role in
preventing urothelial cell-cycle progression, thus keeping
its growth and proliferation to a minimum. If this were
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indeed the case, then one could predict that abrogation of
one of the pRb family members would not be sufficient to
accelerate urothelial growth or tumorigenesis and that the
deficiency of one member might even lead to a compen-
satory induction of another. Both predictions have panned
out. When pRb was ablated from the urothelium using a
urothelium-specific Cre/lox system, no proliferative
changes were observed, let alone the formation of flank
urothelial tumors, despite an exhaustively long follow-up of
a large cohort of pRb-knockout mice [48]. Instead, in pRb-
deficient urothelial cells, there was a marked induction of
p107 and its binding partners/transcription repressors E2F3
and E2F4 [48]. In contrast, p130 was largely unaffected.
Additionally, the loss of pRb function in urothelium
profoundly induced the p53 pathway signals including
p19, p21, bax, and bak. These led to not only cell-cycle
arrest but also to a widespread apoptotic response [48].
These data reveal several overlapping mechanisms whereby
urothelial cells evade tumorigenesis during pRb deficiency
and suggest that a collaborative event(s) may be required in
order for pRb deficiency to be tumorigenic.
4 Activation of RTK pathway components in low-grade
non-invasive urothelial tumorigenesis
Contrary to the resistance of urothelial cells to tumorigen-
esis during pRb and other tumor suppressor deficiency (see
later), these cells are especially susceptible to RTK pathway
activation [49]. Expression of a constitutively active Ha-ras
in transgenic mouse urothelium elicited early-onset hyper-
plasia in all the mice, sixty percent of which eventually
evolved, in mice older 10 months of age, to low-grade, non-
invasive carcinomas that strongly resembled the human
counterparts [50]. Surprisingly, ablation of the Ink4a gene,
which encodes p16Ink4a and p19Arf tumor suppressors
and whose deficiency synergizes with ras activation in
many epithelial and mesenchymal tissues, failed to accel-
erate Ha-ras-induced urothelial hyper-proliferation or tumor
formation [46]. In stark contrast, doubling the gene dosage
of the activated Ha-ras in homozygous Ha-ras transgenic
mice was sufficient to trigger early-onset non-invasive
urothelial carcinomas (Fig. 1) [46]. Consistent with the
proposed growth-inhibitory role of the pRb family in normal
urothelium, all its members were markedly downregulated or
undetectable in Ha-ras-induced urothelial hyperplasia or
urothelial carcinomas [51]. Notably, activated Ha-ras-
induced urothelial carcinomas are invariably low-grade and
non-invasive, in spite of long-term observations [46, 50].
Generation and systematic dissection of urothelium-specific
Ha-ras transgenic mice have, therefore, offered useful
insights into urothelial tumorigenesis indicating that: (1)
over-activation of Ha-ras is both necessary and sufficient to
trigger urothelial tumors along the low-grade and non-
invasive tumor pathway; (2) Ink4a gene products are not
collaborative partners of ras activation in the urothelial
context; and (3) downregulation of pRb family proteins is a
prerequisite for urothelial tumor initiation [46, 49–51].
Additional evidence supporting a critical role of ras
pathway activation in urothelial tumorigenesis comes from
the human studies. It was recently discovered that Costello
syndrome, a developmental disorder exhibiting musculo-
skeletal and nervous system malformation, is caused by
germline mutations in the Ha-ras gene [12]. Patients with
this syndrome begin to develop during early childhood and
adolescence urothelial carcinomas that are of low patho-
logical grade, multi-focal and recurrent, features that
strikingly resemble low-grade, non-invasive urothelial
carcinomas that bear sporadic Ha-ras mutations in adults
[52–54]. Another piece of evidence relates to the finding
that fibroblast growth factor receptor 3 (FGFR3), which is
known to activate the ras signaling pathway [55, 56], is
mutated in 50-80% of low-grade, non-invasive urothelial
carcinomas in humans [57–59]. Mutations in FGFR3 most
frequently involve the receptor's extracellular loop and
affect the cysteine residues: either eliminating or creating a
cysteine [49]. This results in cysteine mis-pairing, confor-
mational change/misfolding and the failure of the mutated
FGFR3 to exit the endoplasmic reticulum. Some FGFR3
mutants are capable of undergoing ligand-independent
activation, constitutively stimulating down-stream effectors
such as ras-GTPase [60, 61]. Interestingly, mutations of
FGFR3 and Ha-ras rarely co-exist in the same tumor [62],
possibly reflecting the functional equivalence of the
mutations in these two genes. Given the fact that Ha-ras
and FGFR3 mutations each occur in ~30% and ~60% of the
low-grade, non-invasive urothelial carcinomas [20, 57–59],
there is reason to believe that mutations of these two genes
can account for the overwhelming majority of this
urothelial tumor variant [49]. It cannot be ruled out that
the remainder of this tumor variant could be caused by
mutations in other ras pathway components such as SOS
and Raf-1 [63, 64]—a possibility that needs to be verified.
Questions remain as to whether FGFR3 mutations alone are
tumorigenic in transgenic mouse models; whether gene
dosage of the FGFR3 mutants, like that of Ha-ras mutants,
plays a role in tumor latency and penetrance; and whether
FGFR3 mutations are required to collaborate with other
tumorigenic event(s) to initiate urothelial carcinomas.
Finally, FGFR3 mutations have been identified primarily
in the low-grade urothelial carcinomas (50–80%), multiple
myelomas (10–15%), and cervical carcinomas (<5%) [65–
67]. It will be of considerable interest to find out why
urothelial cells are particularly susceptible to FGFR3
mutations and whether this is related to a urothelium-
specific carcinogen.
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5 Combined deficiency of pRb and p53 in invasive
urothelial tumorigenesis
For the last two decades, the combined defects of pRb/p53
have been almost synonymous with the muscle-invasive
urothelial carcinomas, largely because of the clinical
correlation between the two [68]. About 50% of the
invasive urothelial carcinomas harbor p53 mutations and
aberrant pRb expression simultaneously and these two
alterations are more significantly associated with poor
prognosis and patient survival than one alteration alone
[69–71]. Despite the close clinical correlation, several
technical constraints precluded the experimental verifica-
tion of whether pRb and p53 deficiency is collaborative in
initiating invasive urothelial carcinomas. pRb inactivation
in mice in a global manner resulted in embryonic lethality
due to severe abnormalities in hematopoietic and neurolog-
ical systems [72–74]. Although mice globally defective in
p53 survived to term, they succumbed to thymic lympho-
mas and soft tissue sarcomas 3–7 months of age when
urothelium appeared completely normal [14, 47]. The lack
of early-onset urothelial tumorigenesis in global p53
knockout mice suggests that p53 deficiency is insufficient
to provoke urothelial tumors, although one could argue that
the combined deficiency of p53 and pRb may be sufficient.
Such a scenario could be supported in part by the
compensatory induction of p53 pathway in pRb-deficient
cells and by the fact that defects of the two genes co-exist
in nearly half of the muscle-invasive bladder cancers in
humans [69–71]. With the help of a urothelium-specific
knockout system [75], pRb and p53 were recently ablated
either alone or in a combination in the urothelial cells [48].
Unlike the global p53 knockout where mice died early in
life, conditional p53 inactivation permitted analyses of the
long-term urothelial effects of p53 deficiency. Nevertheless,
with the exception of late-onset, localized urothelial atypia,
no urothelial tumors were detected throughout the 30-
month observation period [48]. Therefore, p53 deficiency
per se, like that of pRb, is not tumorigenic within the
urothelial context. When p53 deficiency was combined
with pRb deficiency in the double knockout mice, the
former effectively abrogated the cell-cycle arrest and
apoptotic responses provoked by the latter. Unexpectedly,
however, even the combined deficiency of p53 and pRb
only produced late-onset, simple urothelial hyperplasia, and
low-grade, superficial papillary tumors in a small fraction
Fig. 1 Dosage-dependence in the activation of ras pathway effectors
leading to low-grade, non-invasive urothelial tumorigenesis in the
transgenic mice. Low-level urothelial expression of an activated Ha-
ras primarily induces MAPK pathway components and urothelial
hyperplasia, without provoking urothelial tumors. However, doubling
the activated Ha-ras transgene dosage hyper-activates Akt and STAT
pathways, resulting in low-grade, non-invasive urothelial tumors.
STAT activation may be caused by growth factor (GFs) and cytokines
(CTKs) during epithelial/mesenchymal interaction and/or by the
functional inactivation of PTEN through C-terminal phosphorylation.
Mutations in fibroblast growth factor receptor 3 (FGFR3), which is
known to constitutively activate ras GTPase, are likely to transmit
signals and induce urothelial tumors in a similar manner. This figure
was reprinted with permission from Ref. 46
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(<5%) of the double knockout mice [48]. No invasive
urothelial carcinoma was observed despite long-term
observations of several independent cohorts. While incapa-
ble of forming full-fledged invasive carcinomas spontane-
ously, 50% of the p53/pRb-double null mice developed
muscle-invasive urothelial carcinomas after exposure to a
0.01% BBN for 10 weeks [48]. At the same dosage and
time frame, none of the single-null mice lacking either p53
or pRb, or the double null mice lacking one p53 and one
pRb allele, developed any urothelial tumors. Taken together,
these data provide compelling experimental evidence indi-
cating that the combined defects of p53 and pRb are
necessary but not sufficient to initiate invasive urothelial
carcinomas and suggest that other genetic alterations are
required to trigger this urothelial tumor type. Given the fact
that conditional inactivation of both p53 and pRb elicits
flank tumors in several non-epithelial tissues [76, 77], the
observed effects with these two genes deleted in the
urothelial cells provide yet another example of the context-
dependency of tumorigenicity not only by oncogenes, but
also by tumor suppressor genes.
6 Potential involvement of pRb family proteins
in invasive urothelial tumorigenesis
The lack of tumorigenesis in urothelial cells deficient for
both p53 and pRb created a discrepancy with results
obtained from transgenic mice urothelially expressing an
SV40 large T antigen, which is known to functionally
inactivate p53 and pRb. These mice, particularly those
harboring high SV40T transgene copies, consistently
developed high-grade urothelial lesions resembling carci-
noma in situ followed by muscle invasion and metastasis
[78, 79]. Similar results of invasive urothelial tumorigenesis
were obtained from an independent transgenic model in
which SV40T was driven by a keratin 5 promoter that is
transcriptionally active in urothelial as well as several non-
urothelial epithelial tissues [80]. Although the oncogenic
effects of SV40T reach well beyond its ability to inactivate
p53 and pRb, the specific inhibitory effect of SV40T on the
entire pRb family proteins such as p107 and p130 is of
particular interest [16, 81]. As discussed earlier, there was a
marked induction of p107 in urothelial cells deficient for
pRb [48]. This response remained high when the urothelial
cells were made both pRb- and p53-deficient. In both
situations, p107 induction was accompanied by an in-
creased expression of E2F3 and E2F4, two transcription
repressors/growth inhibitors.
p107 shares a similar structure with the other two pRb
family members (pRb and p130) in possessing a pocket
domain for protein interaction and they act in concert to
restrict cell-cycle progression from G1 to S and from G2 to
M phases [82, 83]. Emerging evidence suggests that
different pRb family proteins may carry out distinct
functions by partnering with different downstream E2F
effectors. For instance, pRb binds to so-called activating
E2Fs including E2F1, 2 and 3a, whereas p107 and p130
bind to repressive E2Fs such as E2F3b, 4 and 5 [84].
Because E2F4 and 5 do not have a nuclear translocation
signal, their binding to p107 and p130 is crucial for their
role in transcription repression. While pRb was a well-
established tumor suppressor, the role of p107 and p130 in
tumorigenesis is much less clear.
It appears that p107 induction in urothelium may
represent a compensatory tumor defense in response to
pRb deficiency and that p107 deficiency could be syner-
gistic with pRb and p53 deficiency to trigger urothelial
tumor formation (Fig. 2). Indeed, in BBN-treated pRb/p53
double null mice that developed invasive urothelial carci-
nomas, p107 was significantly downregulated [48]. A close
collaborative role between p107 deficiency and that of pRb
and p53 has been demonstrated in retinal and epidermal
tumorigenesis [85, 86]. Direct proof of whether this
synergistic role applies to the urothelial cells has yet to be
made available, perhaps via the generation of compound
knockout mice lacking all three proteins.
Fig. 2 Collaborative effects between pRb family proteins and p53 in
invasive urothelial tumorigenesis. a Ablation of pRb specifically in
urothelium leads to E2F1 over-expression which in turn up-regulates the
p53 pathway and pRb family protein p107 along with transcriptional
repressor E2F4. These compensatory urothelial defenses cause urothe-
lial cells to undergo cell-cycle arrest and apoptosis. b Additional
ablation of p53 in urothelial cells lacking pRb effectively blunted
apoptotic response, resulting in late-onset hyperplasia and nuclear
atypia. c Treatment of urothelial cells lacking both pRb and p53 with
bladder carcinogen BBN down-regulates p107 and triggers invasive
urothelial tumorigenesis. This model emphasizes the collaborative
effects among pRb family proteins and p53 in invasive urothelial tumor
initiation. This figure was reprinted with permission from Ref. 48
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7 Emerging role of PTEN deficiency
The phosphatase and tensin homology (or PTEN), located
on human chromosome 10, is a lipid phosphatase that
dephosphorylates phosphoinositide-3,4,5-triphosphate
(PI3P). In doing so, the 55-kDa protein antagonizes the
activity of PI3 kinase, preventing it from activating
downstream pro-proliferation and -survival signals, espe-
cially AKT, and leading to growth inhibition [87, 88].
Inactivation of PTEN in vitro enhances oncogenic transfor-
mation and reintroduction of PTEN in cells lacking it
suppresses cell growth [89–91]. While homozygous dele-
tion of PTEN in mice causes embryonic lethality [92], mice
heterozygous for the gene develop multi-organ tumors
particularly those of endometrium, liver, prostate, and
thyroid [93]. Tumor formation in heterozygous mice is
associated with a concomitant loss of the wild-type allele in
the tumor cells, suggesting that, like most other tumor
suppressors, inactivation of both alleles is required for
complete gene inactivation [93, 94]. This concept of
inactivation of both tumor suppressor gene alleles as a
prerequisite for tumor predisposition has received strong
support from more recent tissue-specific PTEN knockout
models [95, 96]. Not surprisingly, loss-of-function muta-
tions or deletion of PTEN have become one of the most
commonly identified mutations in human tumors [87, 97].
Finally, patients with Cowden's disease and other related
syndromes that harbor germline mutations in the PTEN
gene are susceptible to tumor formation, particularly in the
mammary and thyroid glands [98]. These and other
observations firmly establish PTEN as a potent tumor
suppressor whose deficiency plays a major role in the
tumorigenic process.
Although PTEN has been proven to be a general tumor
suppressor, little was known until recently about whether its
deficiency plays a significant role in bladder tumorigenesis.
Ablation of loxP-flanked PTEN by Cre recombinase under
the control of the promoter of fatty acid binding protein 1
gene, which restricted PTEN inactivation to mainly
genitourinary tissues, elicited urothelial hyperplasia and a
low percentage (10–20%) of bladder tumors after long-term
follow-up [95, 99]. These data suggest that the absence of
PTEN alone is insufficient for bladder tumor initiation
and that PTEN deficiency requires another genetic event
to be fully tumorigenic. An interesting study published
recently pointed to the possibility that p53 deficiency
could be such a pivotal collaborating event [100]. By co-
deleting loxP-flanked PTEN and p53 genes in the bladder
using an intravesically instilled, adenovirus-driven Cre
recombinase, the authors found invasive bladder carcino-
mas in the double knockout mice, but not in the single
gene knockout mice. Consistent with the loss of PTEN as
an upstream inhibitor of PI3K/AKT signaling pathway,
tumor formation in the double null mice was associated
with a strong activation of mammalian target of rapamycin
(mTOR) [100]. In the same study, the authors found co-
deletion of “floxed” p53 and pRb in the urothelium by
adenovirus-driven Cre not to be tumorigenic, thus lending
independent support to the results obtained from p53/pRb
inactivation via constitutively expressed urothelial Cre
(see Section 5).
As for human studies, several independent groups found
allelic loss or imbalance of chromosome 10q, where PTEN
resides, to be present in 30–50% of the human bladder
tumors [101–105]. However, homozygous deletion of
PTEN occurs in only about 0–6% of the tumors. Surpris-
ingly, in patients exhibiting loss of one PTEN allele,
mutations in the remaining allele are infrequent, ranging
from 0–10% in most cohorts [101, 106, 107]. On a protein
level, absent PTEN expression is found in ~6% of the
tumors, a rate similar to that of homozygous gene deletion
[99]. Together, these data reveal a recurring theme that
structural damage affecting both PTEN alleles is infrequent
in the majority of human bladder cancers, raising the
interesting possibility that functional inactivation of PTEN
contributes significantly to PTEN deficiency. This is clearly
an important area that requires further investigation.
8 Mechanisms of urothelial tumor progression
One of the key findings from the genetically engineered
mice is that distinct genetic alterations clearly underlie
phenotypically divergent urothelial tumors. Thus, ras
pathway activation produces exclusively the low-grade,
non-invasive urothelial carcinomas [46, 50]. On the other
hand, p53 inactivation along with deficiency in the pRb
family proteins or in PTEN is almost exclusively associated
with high-grade, invasive urothelial carcinomas [48, 100].
Thus far, few studies have been carried out to examine what
genetic or epigenetic alterations are responsible for con-
verting the low-grade non-invasive urothelial tumors into
the high-grade invasive ones. Although a number of factors
could come into play, the low-grade urothelial tumors
triggered by the Ha-ras mutation seem to have acquired
several major tumor barriers, as evidenced by the induction
of multiple CDK inhibitors/tumor suppressors such as p15,
p16, p21, p27, and p53 [46, 51]. These molecules are
known to play important roles in mediating premature
senescence, apoptosis, and DNA damage response. It is
conceivable that overcoming one or more barriers will be
necessary in order for the low-grade urothelial tumors to
transit to high-grade ones. Understanding this important
issue will help provide new clues as to how the progression
of urothelial tumors can be more accurately predicted
clinically.
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9 Diagnostic and therapeutic implications
As the molecular bases distinguishing the two urothelial
carcinoma variants start to be unraveled, it is more realistic
than ever to devise variant-specific intervention strategies.
Because ras pathway activation accounts for an overwhelm-
ing majority of the low-grade non-invasive urothelial
carcinomas, inhibitors of key pathway effectors in partic-
ular FGFR3, ras, Akt, Stat3/5, will likely have an important
therapeutic effect in treating and/or reducing the recurrence
frequency of this major urothelial tumor variant [46, 49].
Such pharmaceutical-based therapies will significantly
reduce the need for surgical intervention, thus minimizing
patient suffering and economic burden. Similarly, the
findings that deficiency of p53 cooperates with that of
pRb and p107 or PTEN to induce invasive urothelial
carcinomas [48, 100] suggest that replacing and/or restoring
the function of one or more of these tumor suppressors
could be an attractive alternative or an adjunct to radical
cystectomy and chemotherapy for this often deadly urothe-
lial tumor variant. Viral vector-based gene therapies based
on pRb or p53 alone have already been tested for human
urothelial carcinomas, showing early promise [108, 109].
Combination therapies that include not just one but two or
more wild-type tumor suppressors will likely be more
effective than single gene therapy. Finally, a combination of
the currently used markers such as p53 and pRb with newer
markers such as p107 and PTEN could be more reliable
than single markers in predicting the prognosis of patients
with bladder cancers [48, 100].
10 Summary and prospective
Since the introduction of transgenic and knockout models
into the bladder cancer field, the technology has been
instrumental for improving the understanding of the
molecular pathogenesis of this disease. It has helped better
define the tumorigenicity, or the lack thereof, of oncogenic
alterations prevalent in human bladder cancer specimens;
identify key signals whose activation drives urothelial
tumorigenesis and progression; understand the intricate
interplay and the collaborative relationships among diverse
oncogenic defects; reveal distinct lesions preceding the
development of a urothelial tumor variant; attach specific
meanings to why there are phenotypically divergent path-
ways of urothelial tumorigenesis; and provide in vivo
platforms for testing novel preventive and therapeutic
strategies. Such information has been proven quite comple-
mentary to that obtained from the analysis of human
specimens. The hypotheses generated from the animal
models are readily testable in humans as well. Looking
ahead, there is still a great deal to be learned about what
underlies each of the two major pathways of urothelial
tumorigenesis. For instance, while ras pathway activation
could account for an overwhelming majority of the low-
grade non-invasive urothelial carcinomas, about half of the
muscle-invasive urothelial carcinomas in humans have no
known defects in p53, pRb, or PTEN. Are these tumors
caused by some of the known genetic defects or by other yet-
to-identified genetic defects? As the transgenic/knockout
technology matures, new questions can be asked with new
levels of sophistication. There should be little doubt that
future models will be more useful and relevant than those
now in existence in helping elucidate the molecular
pathogenesis of bladder cancer and improve target-based
clinical management.
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